sábado, 7 de noviembre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· October 31, 2025

The Zacks Analyst Blog Highlights Broadcom, Johnson & Johnson, Palantir Technologies, Fossil Group and Moving iMage

View original at finance.yahoo.com
The Zacks Analyst Blog Highlights Broadcom, Johnson & Johnson, Palantir Technologies, Fossil Group and Moving iMage For Immediate Release Chicago, IL – October 31, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Management guides for further margin gains as SG&A savings and licensing efficiencies take hold

    80% confidence

  • J&J has rapidly advanced its pipeline this year that will help drive growth through the back half of the decade

    80% confidence

  • The turnaround plan targets $30 million in FY25 savings through supply chain, pricing and vendor initiatives

    80% confidence

  • Roughly more than 90% of Broadcom's largest 10,000 customers have adopted VCF as of fiscal third quarter

    80% confidence

  • Since 2000, Zacks' top stock-picking strategies have blown away the S&P's +7.7% average gain per year with average gains of +48.4%, +50.2% and +56.7% per year

    80% confidence

  • Broadcom expects fourth-quarter fiscal 2025 AI revenues to jump 66% year over year to $6.2 billion

    80% confidence

  • J&J expects sales growth in both segments to be higher in 2026

    80% confidence

  • Gross margins in fiscal fourth quarter are expected to contract sequentially

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,996
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,996 hechos verificados con la fuente5,552 documentos fuente archivados
Consulta estos datos → isubstrate.com
The Zacks Analyst Blog Highlights Broadcom, Johnson & Johnson, Palantir Technologies, Fossil Group and Moving iMage — Source | Via News | es.VIA.NEWS